AzTrials
AzTrials

Metabolic HealthNCT07155915

Effects of Cherry Consumption on Metabolic Health

A study testing Sweet cherries, 280 g daily for 42 days in people with Metabolic Health, run by Instituto Politécnico da Guarda at 1 site in Portugal.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is designed to evaluate the effects of daily sweet cherry consumption on markers of metabolic health in adults. Cherries are rich in bioactive compounds, such as anthocyanins and phenolic acids, which may help reduce oxidative stress, inflammation, and early risk factors for conditions like type 2 diabetes… Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Metabolic Health
What is being tested?
Sweet cherries, 280 g daily for 42 days
Could I receive a placebo?
No, everyone receives an active treatment
How many people
27 participants
Where
1 sitePortugal
Study dates
14 May 2024to 23 Jul 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age 18-65 years old
  • Healthy individuals with no known metaboli disorders

Who cannot join

  • Alcohol consumption
  • Smoking
  • Adverse or allergic reaction to cherries
  • Use of antibiotics, anxiolytics, or dietary supplements
  • Pregnancy or lactation
  • Weight changes greater than 10% in the previous year.

Trial locations and contacts

1 site in 1 country.

Portugal1 site

  • Instituto Politécnico da Guarda

    Guarda

Other trials in Portugal

About this study

Official title: Effects of Cherry Consumption on Metabolic Health: A Pilot Clinical Study on Healthy Adults

This study is designed to evaluate the effects of daily sweet cherry consumption on markers of metabolic health in adults. Cherries are rich in bioactive compounds, such as anthocyanins and phenolic acids, which may help reduce oxidative stress, inflammation, and early risk factors for conditions like type 2 diabetes and cardiovascular disease. Participants will consume 280 grams of fresh sweet cherries every day for 42 consecutive days. Blood and urine samples will be collected at four time points: before the intervention (baseline), at day 21, at day 42 (end of the intervention), and two weeks after stopping cherry consumption.

The study will measure changes in blood sugar regulation, markers of inflammation, oxidative stress, liver and kidney function, and immune response. Waist circumference and body mass index will also be recorded.

The aim of this study is to test whether daily cherry consumption can support metabolic health in healthy adults and to provide data that may inform larger and longer clinical trials in the future.

Being tested
Sweet cherries, 280 g daily for 42 days
Keywords
cherry consumption, metabolic health, phenolic compounds

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sweet cherries, 280 g daily for 42 daysDietary supplement

    Participants will consume 280 grams of fresh sweet cherries daily for 42 consecutive days. Cherries are provided in pre-weighed portions to be consumed in the morning on an empty stomach

Study groups in NCT07155915
Study groupRoleWhat they receive
Daily Sweet Cherry ConsumptionExperimentalParticipants in this arm will consume 280 grams of fresh sweet cherries (Prunus avium, "Prime-Giant" variety) every day for 42 consecutive days.
Receives: Dietary Supplement: Sweet cherries, 280 g daily for 42 days

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in fasting glucose

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  2. Changes in HbA1c

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  3. Changes in estimated average glucose

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  4. Changes in insulin

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  5. Changes in IL-6

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  6. Changes in AGP-1

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  7. Changes in C-reactive protein

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  8. Changes in gluthatione peroxidase

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  9. Changes in gluthatione reductase

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  10. Changes in glutamate dehydrogenase

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

Secondary outcomes (31)

  1. Changes in aspartate aminotransferase

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  2. Changes in alanine transaminase

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  3. Changes in gamma-glutamyl transferase

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  4. Changes in total bilirubin

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  5. Changes in conjugated bilirubin

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  6. Changes in unconjugated bilirubin

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  7. Changes in lactate dehydrogenase

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  8. Changes in total proteins

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  9. Changes in albumin

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  10. Changes in urea

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  11. Changes in creatinine

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  12. Changes in microalbumin

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  13. Changes in uric acid

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  14. Changes in iron

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  15. Changes in TIBC

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  16. Changes in transferrin

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  17. Changes in ferritin

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  18. Changes in amylase

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  19. Changes in lipase

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  20. Changes in IgA

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  21. Changes in IgG

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  22. Changes in IgM

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  23. Changes in total IgE

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  24. Changes in rheumatoid factor

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  25. Changes in antistreptolysin O

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  26. Changes in triglycerides

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  27. Changes in total cholesterol

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  28. Changes in HDL cholesterol

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  29. Changes in LDL cholesterol

    Measured: Baseline, Day 21, Day 42 and 2 weeks post-intervention

  30. Changes in waist circumference

    Measured: Baseline and Day 42

  31. Body Mass Index

    Measured: Baseline and Day 42

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Sep 2025
  2. Study start14 May 2024
  3. Primary completion23 Jul 2024
  4. Study completion23 Jul 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
27 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07155915
Sponsor's protocol ID
PRR-C05-i03-I-000143
Status last verified
Aug 2025
First submitted
20 Aug 2025
Last updated
4 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Sweet cherries, 280 g daily for 42 days in people with Metabolic Health, run by Instituto Politécnico da Guarda at 1 site in Portugal.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in fasting glucose (time frame: Baseline, Day 21, Day 42 and 2 weeks post-intervention). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07155915.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in